These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20040526)

  • 41. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension.
    Giannelli G; Iannone F; Marinosci F; Lapadula G; Antonaci S
    Curr Med Res Opin; 2005 Mar; 21(3):327-32. PubMed ID: 15811199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Digital ulcers: overt vascular disease in systemic sclerosis.
    Steen V; Denton CP; Pope JE; Matucci-Cerinic M
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii19-24. PubMed ID: 19487218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of bosentan on the skin lesions: an observational study from a single center in Japan.
    Funauchi M; Kishimoto K; Shimazu H; Nagare Y; Hino S; Yano T; Kinoshita K
    Rheumatol Int; 2009 May; 29(7):769-75. PubMed ID: 19037604
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R; Shariat K; von Wilmowsky H; Böhm M
    Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L; Shapiro L; Fiorentino D; Baron M; Shanahan J; Sule S; Hsu V; Rothfield N; Steen V; Martin RW; Smith E; Mayes M; Simms R; Pope J; Kahaleh B; Csuka ME; Gruber B; Collier D; Sweiss N; Gilbert A; Dechow FJ; Gregory J; Wigley FM
    Arthritis Rheum; 2009 Mar; 60(3):870-7. PubMed ID: 19248104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis.
    Cutolo M; Zampogna G; Vremis L; Smith V; Pizzorni C; Sulli A
    J Rheumatol; 2013 Jan; 40(1):40-5. PubMed ID: 23118114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
    Sfikakis PP; Papamichael C; Stamatelopoulos KS; Tousoulis D; Fragiadaki KG; Katsichti P; Stefanadis C; Mavrikakis M
    Arthritis Rheum; 2007 Jun; 56(6):1985-93. PubMed ID: 17530638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.
    Seibold JR; Denton CP; Furst DE; Guillevin L; Rubin LJ; Wells A; Matucci Cerinic M; Riemekasten G; Emery P; Chadha-Boreham H; Charef P; Roux S; Black CM
    Arthritis Rheum; 2010 Jul; 62(7):2101-8. PubMed ID: 20506355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
    Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
    Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
    [No Abstract]   [Full Text] [Related]  

  • 57. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
    Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.